Drew Holzapfel is a Managing Partner at High Lantern Group, where he oversees the firm’s works with top biopharmaceutical companies to drive market readiness, position key policy issues, build partnerships, and gain third-party organization support.
Drew has held roles within the federal government and the private sector, including at pharmaceutical companies, device manufacturers, and consulting firms. His experience has included positions at Pfizer, The White House, and the U.S. Department of Health and Human Services.
Drew is also committed to helping nonprofits and coalitions develop their positioning strategies and strengthen their impact. He’s a founding board member of the Global Alzheimer’s Platform Foundation and the Commit2Kind anti-bullying nonprofit. He’s also the Executive Director of the Global CEO Initiative on Alzheimer’s Disease, and was formerly the President and on the board of UsAgainstAlzheimer’s.